Core Insights - MarketAxess (MKTX) reported quarterly earnings of $2 per share, exceeding the Zacks Consensus Estimate of $1.94 per share, and up from $1.72 per share a year ago, representing an earnings surprise of +3.09% [1] - The company achieved revenues of $219.46 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.59% and increasing from $197.66 million year-over-year [2] - MarketAxess has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Financial Performance - The earnings surprise of +3.09% for the recent quarter follows a previous surprise of +2.75% when the company reported earnings of $1.87 per share against an expectation of $1.82 [1][2] - The current consensus EPS estimate for the upcoming quarter is $1.87, with projected revenues of $217.2 million, and for the current fiscal year, the EPS estimate is $7.50 on revenues of $866.46 million [7] Market Position - Despite the strong earnings report, MarketAxess shares have underperformed the market, losing about 8.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The Zacks Industry Rank places the Financial - Investment Bank sector in the top 5% of over 250 Zacks industries, suggesting a favorable outlook for companies within this sector [8]

Company Performance - DNOW reported quarterly earnings of $0.27 per share, exceeding the Zacks Consensus Estimate of $0.22 per share, and showing an increase from $0.25 per share a year ago, representing an earnings surprise of +22.73% [1] - The company posted revenues of $628 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.19%, although this is a slight decrease from year-ago revenues of $633 million [2] - DNOW has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - DNOW shares have increased approximately 17.1% since the beginning of the year, compared to a 7.1% gain in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $618.25 million, and for the current fiscal year, it is $0.86 on revenues of $2.42 billion [7] Industry Outlook - The Manufacturing - General Industrial industry, to which DNOW belongs, is currently ranked in the top 16% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact DNOW's stock performance [5]

Core Viewpoint - MRC Global reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, but down from $0.31 per share a year ago, indicating an earnings surprise of +8.70% [1] Financial Performance - The company posted revenues of $798 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.35%, although this is a decrease from year-ago revenues of $832 million [2] - Over the last four quarters, MRC has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - MRC shares have increased approximately 12.4% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates of $0.32 for the coming quarter and $0.87 for the current fiscal year, alongside revenues of $832.9 million and $3.04 billion respectively [7] - The estimate revisions trend for MRC was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Steel - Pipe and Tube industry, to which MRC belongs, is currently in the top 23% of over 250 Zacks industries, suggesting a positive outlook as the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Fortrea Holdings Inc. reported quarterly earnings of $0.19 per share, significantly exceeding the Zacks Consensus Estimate of $0.06 per share, and showing a turnaround from a loss of $0.03 per share a year ago, indicating strong performance in the latest quarter [1][2] Financial Performance - The company achieved revenues of $710.3 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 12.60% and reflecting an increase from $662.4 million in the same quarter last year [2] - Over the last four quarters, Fortrea has exceeded consensus EPS estimates two times and topped revenue estimates three times [2] Stock Performance - Fortrea Holdings Inc. shares have declined approximately 64.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.14 on revenues of $607.87 million, while for the current fiscal year, the estimate is $0.42 on revenues of $2.5 billion [7] - The outlook for the Medical - Biomedical and Genetics industry, where Fortrea operates, is currently in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8]

Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]

分组1 - Hippo Holdings Inc. reported quarterly earnings of $0.65 per share, exceeding the Zacks Consensus Estimate of a loss of $0.65 per share, and showing improvement from a loss of $1.64 per share a year ago, resulting in an earnings surprise of +200.00% [1] - The company achieved revenues of $117.3 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.59% and increasing from $89.6 million year-over-year [2] - Over the last four quarters, Hippo Holdings has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - Hippo Holdings shares have increased approximately 3.3% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.31 on revenues of $122.53 million, and for the current fiscal year, it is -$2.86 on revenues of $477.03 million [7] 分组3 - The Zacks Industry Rank indicates that the Insurance - Multi line sector is currently in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - The estimate revisions trend for Hippo Holdings was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Core Insights - Claritev Corporation (CTEV) reported quarterly earnings of $0.32 per share, significantly beating the Zacks Consensus Estimate of a loss of $2.69 per share, and improving from a loss of $1.2 per share a year ago, resulting in an earnings surprise of +111.90% [1] - The company generated revenues of $241.57 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.38% and showing an increase from $233.48 million in the same quarter last year [2] - Claritev Corporation's stock has increased approximately 167.4% year-to-date, outperforming the S&P 500's gain of 7.1% [3] Earnings Outlook - The future performance of Claritev Corporation's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$2.62 on revenues of $231.53 million, and for the current fiscal year, it is -$12.20 on revenues of $928.06 million [7] Industry Context - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]

Summary of Geopark's Quarterly Earnings Report Core Viewpoint - Geopark reported quarterly earnings of $0.27 per share, exceeding the Zacks Consensus Estimate of $0.15 per share, but down from $0.48 per share a year ago, indicating a significant earnings surprise of +80.00% [1] Financial Performance - The company posted revenues of $119.79 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.68%, but down from $190.2 million year-over-year [2] - Over the last four quarters, Geopark has surpassed consensus revenue estimates four times, but only once for EPS estimates [2] Stock Performance and Outlook - Geopark shares have declined approximately 31.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $112.37 million, and for the current fiscal year, it is $0.80 on revenues of $473.84 million [7] Industry Context - The Oil and Gas - Exploration and Production - United States industry, to which Geopark belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Geopark's stock may be influenced by the overall outlook of the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Nine Energy Service reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, and an improvement from a loss of $0.4 per share a year ago, indicating an earnings surprise of -13.64% [1] - The company posted revenues of $147.25 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.54% and showing an increase from year-ago revenues of $132.4 million [2] - Nine Energy shares have declined approximately 35% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $137.9 million, and for the current fiscal year, it is -$0.94 on revenues of $563.2 million [7] - The Zacks Industry Rank for Oil and Gas - Field Services is currently in the bottom 8% of over 250 Zacks industries, indicating a challenging environment for the sector [8]

Core Viewpoint - Ardent Health, Inc. reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.30 per share, and showing an increase from $0.35 per share a year ago, indicating a strong earnings surprise of +73.33% [1] Financial Performance - The company achieved revenues of $1.65 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.91%, compared to $1.47 billion in the same quarter last year [2] - Over the last four quarters, Ardent Health has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance - Ardent Health shares have declined approximately 39.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.72 on revenues of $1.63 billion, and for the current fiscal year, it is $1.92 on revenues of $6.33 billion [7] - The outlook for the Medical Services industry, where Ardent Health operates, is currently in the top 35% of Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]